GLYCOMIRA, LLC
Salt Lake City, UT · Medtech
Point-of-care diagnostic test for eosinophilic chronic rhinosinusitis using sinonasal swab and immunologic marker detection
- Grants
- $7.0M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | $7,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $297,614 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | $364,866 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | $381,446 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $781,547 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $841,614 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $783,698 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $1,975,971 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | $976,018 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis | $304,921 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis | $290,351 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2191 | LIVIVOS INC. | — | — |
| 2192 | KINETICA LABS, INC. | — | — |
| 2193 | SPOC PROTEOMICS INC. | — | — |
| 2194 | GLYCOMIRA, LLC | — | — |
| 2195 | Mozaic Medical Inc | — | $225K |
| 2196 | Aikili Biosystems Inc | — | — |
| 2197 | NEOCHORD INC | — | $63M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.